Post-earnings recap
Reported
Wed, Aug 5, 2026
EPS actual
$-0.09
EPS est.
$-0.06
EPS surprise
-50.00%
1-day move
-2.34%
Cytek Biosciences reported a loss of $0.09 per share, which was below expectations, leading to a 2.34% decline in stock price. The lack of revenue figures and management commentary adds uncertainty to the outlook. Investors may be cautious as the company did not provide any guidance for future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.09 | N/A | -50.00% |
| Revenue | N/A | N/A | N/A |
No transcript is on record, and the analysis is based solely on numerical results.
Cytek Biosciences, Inc. is a health care company specializing in life sciences tools and services, particularly in advanced cell analysis technologies. With a market cap of $1 billion, it plays a crucial role in the growing field of biotechnology, which is increasingly important for research and clinical applications.
Last quarter
In Q1 2026, Cytek reported an EPS of -$0.15, missing estimates by a significant margin. The stock reacted negatively, dropping 0.40% the following day.
EPS beat streak
0Q
EPS beat rate
25%
Avg EPS surprise
-137.03%
Avg 1-day reaction
+0.42%
Overall, expectations for Cytek's upcoming earnings are uncertain due to the lack of analyst estimates and mixed historical performance. Investors are particularly focused on profitability and revenue growth.
Bull case
The optimistic view hinges on a potential turnaround in profitability, with investors hoping for a surprise positive EPS and strong revenue growth that could signal a recovery.
Bear case
On the downside, continued losses and disappointing revenue could lead to further declines in stock price, especially given the recent history of earnings misses.
The print will turn on these.
Q1
What will the EPS be for Q2-2026?
The EPS figure will be critical in determining if Cytek can show signs of profitability or if losses will continue to weigh on investor sentiment.
Q2
How does management plan to address revenue growth?
Investors will be looking for concrete strategies from management on how to improve revenue, especially given the recent earnings misses.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±12.7%
Why consensus could be wrong
The Street may be underestimating Cytek's potential for a turnaround given its recent investments in product innovation and market expansion.
Supporting evidence
Despite recent earnings misses, the company has a strong product pipeline that could lead to improved performance.
Options pricing suggests that investors are anticipating a significant move, indicating a belief in potential volatility and opportunity.
The historical EPS beat rate of only 25% may not fully reflect the company's capacity for recovery in the current market environment.
Key risk
If the EPS comes in above -$0.10, it could shift market sentiment significantly.
Pre-commit to what would confirm each case.
The core debate this quarter revolves around whether Cytek can shift from losses to profitability and how effectively it can grow revenue.
Bull confirmed if
A positive EPS surprise of at least $0.05 would confirm the bull case and suggest a turnaround in profitability.
Bear confirmed if
An EPS of -$0.20 or worse would confirm the bear case, indicating ongoing struggles.
What the market is pricing for the move.
Implied Move
±233.89%
Historical Avg
±2.0%
The options market is pricing in a significant move, suggesting that investors expect high volatility around the earnings announcement.
Options are pricing ±233.9% while CTKB has averaged ±2.0% over the last 8 prints — setup is pricing rich.
30d HV
70.1%
Smart-money positioning from the most recent 13F filings.
Institutional
62.95%
of float
Insider
8.47%
of float
Holders
208
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
9,578,643 sh · $51.1M
7.37%
-43.7%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Cytek beats expectations, history suggests the stock could rise by an average of 3.59%, confirming a positive turnaround narrative.
In line / cautious
If results are in line with expectations, the stock may experience a muted reaction as investors await further clarity on growth strategies.
Miss
If the company misses again, history suggests a potential decline of about 0.53%, which could further erode investor confidence.
The lines on the call that would change the story.
Millennium Management Llc
9,338,010 sh · $49.9M
7.18%
48.4%
Boston Partners
7,660,943 sh · $40.9M
5.89%
32.0%
HHLR Advisors, LTD
6,657,030 sh · $35.5M
5.12%
Flat
Topline Capital Management, LLC
6,283,450 sh · $33.6M
4.83%
-11.1%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.